Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.44 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180947 | 1.00 | KMT2A (0.47) | KMT2AMAPK1CTSSCTSKSCN9A | |
| SCHEMBL182152 | 0.91 | PABPC1 (0.47) | KMT2AMAPK1CTSSCTSKSCN9A | |
| SCHEMBL182153 | 0.91 | PABPC1 (0.47) | KMT2AMAPK1CTSSCTSKSCN9A | |
| SCHEMBL181979 | 0.89 | CCKBR (0.47) | CALCRLCCKBR | |
| SCHEMBL31163618 | 0.87 | MAPK1 (0.45) | KMT2AMAPK1ALDH1A1CCKBRITGB3 | |
| SCHEMBL182031 | 0.87 | MAPK1 (0.45) | KMT2AMAPK1ALDH1A1CCKBRITGB3 | |
| SCHEMBL182030 | 0.87 | MAPK1 (0.45) | KMT2AMAPK1ALDH1A1CCKBRITGB3 | |
| SCHEMBL181989 | 0.87 | USP30 (0.38) | KMT2AMAPK1CALCRLCCKBR | |
| SCHEMBL181976 | 0.86 | CCKBR (0.41) | CALCRLCCKBR | |
| SCHEMBL181977 | 0.86 | CCKBR (0.41) | CALCRLCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401268-B1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8697877-B2 | Oxyindole derivatives with motilin receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2401268-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RaQualia Pharma Inc (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| WO-2010098145-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | GPR68, GPR88, GPR52 | KMT2A 3436/4885MAPK1 337/4885CTSS 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.